Systemic Lupus Erthematosus: Clinical Trials

6 trials for Systemic Lupus Erthematosus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 not yet recruiting. 6 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Recruiting 4, Not yet recruiting 2
Phase 14Recruiting 3, Not yet recruiting 1
Phase 31Not yet recruiting 1

Follow Systemic Lupus Erthematosus: new trials by email Literature Review of Systemic Lupus Erthematosus trials Research Report on Systemic Lupus Erthematosus

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets - Systemic Lupus Erthematosus
Phase 2 / Phase 3Not yet recruitingChinese SLE Treatment And Research Group2942026-10-152026-09-11
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Budoprutug - Systemic Lupus Erthematosus
Phase 1 / Phase 2RecruitingClimb Bio, Inc.302026-06-302026-10-20
A Study of GR1803 in Systemic Lupus Erythematosus
GR1803 injection - Systemic Lupus Erthematosus, Auto Immune Disease
Phase 1 / Phase 2RecruitingGenrix (Shanghai) Biopharmaceutical Co., Ltd.442026-02-022026-03-10
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2RecruitingPeking University Third Hospital92025-07-012026-09-22
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1 - COVID 19, Influenza
Phase 2RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre6602024-11-202026-10-26

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2)  ·  Myositis (2)  ·  Scleroderma, Systemic (2)  ·  Sjogren's Syndrome (2)  ·  Antiphospholipid Syndrome (1)  ·  Arthritis, Rheumatoid (1)  ·  COVID-19 (1)  ·  Inflammatory Bowel Diseases (1)  ·  Influenza, Human (1)  ·  Lupus Erythematosus, Systemic (1)

Broader conditions

Autoimmune Diseases (4)  ·  Connective Tissue Diseases (4)  ·  Immune System Diseases (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Arthritis (3)  ·  Joint Diseases (3)  ·  Musculoskeletal Diseases (3)  ·  Rheumatic Diseases (3)  ·  Arthritis, Rheumatoid (2)  ·  Cardiovascular Diseases (2)  ·  Dry Eye Syndromes (2)  ·  Eye Diseases (2)  ·  Lacrimal Apparatus Diseases (2)  ·  Mouth Diseases (2)  ·  Muscular Diseases (2)

Interventions

Prednisone (1)  ·  ivarmacitinib (1)

Sponsors

Peking University Third Hospital (2)  ·  Chinese SLE Treatment And Research Group (1)  ·  Climb Bio, Inc. (1)  ·  Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)

Countries

China (4)  ·  Canada (1)

NIH funding

2025 (1)